NeuroQuantix Digitized Drawing Assessment

A precision tablet-based assessment that transforms simple spiral drawing tasks into multidimensional kinematic datasets. Where traditional scales see a single score, NeuroQuantix sees the full biomechanical signature of neurological function.

Request a Technical Brief

The measurement gap in CNS clinical trials

Most neurological assessments used in clinical trials today were developed decades ago. They rely on subjective observer ratings, use ordinal scales with limited granularity, and were never designed to detect the subtle treatment effects that modern therapeutics produce.

The result is a fundamental mismatch: treatments may be working, but the measurement tools cannot see it. Clinical trials fail not because the drug failed, but because the endpoint failed.

Traditional vs. NeuroQuantix

Subjective rating (1-5 scale)
Continuous kinematic measurement
Single composite score
6+ independent data dimensions
Observer-dependent
Fully automated capture
~1Hz effective sampling
240Hz sampling rate
Ceiling/floor effects
Continuous measurement range

Technical Capabilities

Every aspect of the assessment is engineered for regulatory-grade precision and clinical trial deployment.

Real-Time Kinematic Capture

Records velocity, acceleration, pressure, jerk, tilt angle, and spatial position simultaneously at 240 samples per second during structured drawing tasks.

Multidimensional Analysis

Generates 6+ data dimensions from a single assessment. Each dimension provides an independent signal channel for detecting treatment-related change.

Sub-Millimeter Spatial Precision

Detects deviations smaller than 1mm from ideal drawing trajectories. This sensitivity level exceeds what trained clinical raters can reliably distinguish.

Automated Signal Processing

Raw kinematic data is processed through validated algorithms that extract clinically meaningful features without subjective observer interpretation.

Longitudinal Sensitivity

Designed to detect subtle within-subject change over time. Critical for clinical trials measuring treatment effects that evolve gradually across weeks or months.

FDA-Aligned Development

Developed with regulatory acceptance as a core requirement. Assessment design, data handling, and output specifications are built for submission-grade evidence.

Target Indications

NeuroQuantix is applicable across any CNS condition where fine motor function provides a meaningful clinical signal.

Essential tremorParkinson's diseaseMultiple sclerosisHuntington's diseaseCerebellar ataxiasStroke recoveryTraumatic brain injuryNeurodegenerative disordersGene therapy trials (CNS)Drug-induced movement disorders

See what precision measurement reveals

Request a technical overview, sample data outputs, or discuss how NeuroQuantix fits your program's endpoint strategy.

Request Technical Brief